



Caribou Biosciences to Participate in Upcoming Investor Conferences

November 7, 2022

BERKELEY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- [Caribou Biosciences, Inc.](#) (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company's participation in the following investor conferences:

- **Barclays Gene Editing & Gene Therapy Summit**, Virtual
Panel participation on November 14, 2022 at 11:00 am EST
- **Jefferies London Healthcare Conference**, London, United Kingdom
Corporate presentation on November 17, 2022 at 3:50 pm GMT
[Webcast](#)
- **5th Annual Evercore ISI HealthCONx Conference**, Virtual
Fireside chat on November 30, 2022 at 11:45 am EST
[Webcast](#)
- **BofA Securities Biotech SMID Cap Conference**, Boston
Fireside chat on December 7, 2022 at 10:50 am EST
Webcast to be made available on [Events](#) page

For more information, visit the [Events](#) page on Caribou's website. The webcasts will be available on the Caribou website for 30 days after the events.

About Caribou's Novel Next-Generation CRISPR Platform

CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNA; pronounced "chardonnays") that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

About Caribou Biosciences, Inc.

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company's genome-editing platform, including its proprietary Cas12a chRDNA technology, enables superior precision to develop cell therapies that are specifically engineered for enhanced persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of patients with hematologic malignancies and solid tumors.

For more information about Caribou, visit www.cariboubio.com and follow the company @CaribouBio.

"Caribou Biosciences" and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

Caribou Biosciences, Inc. Contacts:

Investors:

Amy Figueroa, CFA
afigueroa@cariboubio.com

Media:

Peggy Vorwald, Ph.D.
pvorwald@cariboubio.com

Investors and Media:

Elizabeth Wolffe, Ph.D., and Sylvia Wheeler
Wheelhouse LSA
lwolffe@wheelhousesa.com
swheeler@wheelhousesa.com